title: First-in-class insomnia drug on the brink of approval nod.
authors.forename: Randy
authors.initials: R
authors.lastname: Osborne
mesh_terms: D001381:Azepines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D017277:Drug Approval; D006801:Humans; D064446:Orexin Receptors; D043562:Receptors, G-Protein-Coupled / Q000037:antagonists & inhibitors; D018013:Receptors, Neuropeptide / Q000037:antagonists & inhibitors; D007319:Sleep Initiation and Maintenance Disorders / Q000188:drug therapy* / Q000378:metabolism; D014230:Triazoles / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D001381:Azepines; D064446:Orexin Receptors; D043562:Receptors, G-Protein-Coupled; D018013:Receptors, Neuropeptide; D014230:Triazoles; C551624:suvorexant